Setting the Standard in Stem Cell Banking
The ACES Award for Industry Champions of the Year recognizes companies that drive progress and innovation within their sectors. Among this year’s recipients, Thailand’s Medeze Group Public Company Limited stands out as the nation’s largest and most established mesenchymal stem cell bank, spearheading advancements in Southeast Asia’s regenerative medicine landscape. Founded in 2010 as Bangkok Stem Cell, Medeze has evolved from a specialized stem cell storage provider into an industry leader renowned for its advanced cell banking technologies, rigorous quality standards, and expansive global reach.
Medeze’s transformation into a market frontrunner reflects its agility in adapting to the evolving healthcare landscape. Initially focusing on umbilical cord blood stem cell banking, the company has since expanded to provide cutting-edge therapies for both preventive and regenerative health. Continuous investment in state-of-the-art technology and strict quality protocols has been central to this journey, reinforcing Medeze’s commitment to scientific excellence.
Advancing Science with Cutting-Edge Technology
Today, Medeze operates the largest world-class stem cell laboratories in Southeast Asia, equipped with Class 10 Cleanroom certification from the National Environmental Balancing Bureau, USA (NEBB), and adherence to American Association of Blood Banks (AABB) standards. This commitment to operational excellence ensures that Medeze maintains the highest levels of safety and efficacy in its regenerative healthcare solutions.
As industry demand evolved, Medeze introduced Thailand’s first mesenchymal stem cell (MSC) storage for umbilical cord tissue and the world’s first adipose tissue storage service. These versatile stem cells have unlocked groundbreaking applications in organ repair and the treatment of major conditions such as heart disease, diabetes, and neurodegenerative disorders.
Additionally, Medeze has positioned itself at the forefront of the longevity science movement, leveraging MSC storage services to meet the growing demand for anti-aging and health optimization therapies. Its foresight in the field has led to ongoing research and development collaborations with leading universities and research institutions across Southeast Asia.
Pioneering NK Cell Immunotherapy
A significant milestone in Medeze’s journey is the development of its NK cell immunotherapy program, a response to the rising global focus on immune health. Natural Killer (NK) cells are essential in the body’s defense against pathogens and cancer cells. Medeze’s patented NK cell therapy, developed in collaboration with Japanese scientists Dr. Junichi Masuyama and Dr. Sanehiko Fujita, enhances immune response, offering a groundbreaking solution in the fight against chronic illnesses and cancer.
This innovation further distinguishes Medeze in the regenerative medicine sector, addressing the increasing demand for advanced immunotherapy solutions worldwide.
Expanding Global Reach and Strategic Partnerships
Medeze’s influence extends far beyond Thailand, with a robust geographical footprint and strategic partnerships across nine countries, including Singapore, Vietnam, Taiwan, Cambodia, Myanmar, and Indonesia. In Thailand alone, Medeze collaborates with 206 hospitals and clinics, including leading medical institutions such as Bangkok Hospital and Bumrungrad Hospital.
This extensive distribution network strengthens Medeze’s accessibility, positioning it as a trusted partner for individuals seeking advanced medical solutions for preventive and restorative healthcare. With representation in Europe, Australia, and New Zealand, Medeze continues to push the boundaries of regenerative medicine on a global scale.
.png)
A Commitment to Sustainability and Corporate Responsibility
Beyond business growth, Medeze’s success is driven by a commitment to corporate responsibility. The Bangkok Stem Cell Foundation, established in 2015, promotes education, research, and treatment in Thailand, reflecting Medeze’s dedication to advancing public health through greater awareness and accessibility to stem cell therapies. This philanthropic initiative underscores the company’s purpose-driven mission beyond financial success.
Financially, Medeze’s strong growth reinforces its industry leadership. With a registered capital of THB 400 million and a debt-free structure, the company has consistently expanded its revenue and profitability, achieving a 35.46% net profit margin by Q3 2023. Stem cell banking services account for over 80% of Medeze’s revenue, with NK cell therapy making up a significant portion of the remaining share. This financial strength enables continued investment in research, development, and capacity expansion in regenerative medicine and immunotherapy.
Shaping the Future of Regenerative Healthcare
With the global stem cell and regenerative medicine market projected to reach USD 26.4 billion by 2026, Medeze is strategically positioned to lead this transformative sector. The company’s mission to deliver longevity and health optimization solutions worldwide sets a new benchmark in regenerative healthcare.
With multiple accolades, including several Frost & Sullivan awards, Medeze’s excellence in operational quality, market foresight, and commitment to customer value continues to be reaffirmed. Winning the Industry Champions of the Year award underscores its role as a frontrunner in regenerative medicine, reinforcing its position as an industry trailblazer.
With a strong financial foundation, cutting-edge scientific advancements, and an unwavering dedication to quality, Medeze embodies the gold standard for success. Its achievements reflect the progressive spirit that the ACES Awards aim to celebrate, setting a new paradigm for the future of healthcare.
